| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
|
Hyodeoxycholic acid (HDCA), a secondary metabolite of bile acid and one of the metabolic byproducts produced by intestinal bacteria, is TGR5 (GPCR19) agonist (EC50 = 0.82 μM).
| Targets |
Microbial Metabolite; Human Endogenous Metabolite
|
|---|---|
| ln Vitro |
Hyodeoxycholic acid is a secondary hydrophilic bile acid formed in the small intestine by disrupted bacterial flora. As a TGR5 agonist, its EC50 in CHO cells is 31.6 μM [1]. Hyodeoxycholic acid (50, 100 μM) increases the expression of genes (Abca1, Abcg1 and Apoe) involved in RAW 264.7 cell resection [2].
|
| ln Vivo |
Hyodeoxycholic acid (HDCA; 1.25% (wt/wt)) significantly reduced fat mass and increased lean body mass in LDLRKO but did not increase serum levels of any organ toxicity markers. Hyodeoxycholic acid blocks atherosclerotic lymphoma lesions at multiple sites in LDLRKO, improves constipation lipoprotein profiles, reduces cholesterol levels and blocks cholesterol absorption efficiency, and increases daily cholesterol excretion through fecal respiration. Hyodeoxycholic acid also improves HDL function, which can be accomplished simply by cholesterol interruption assay [2].
|
| Animal Protocol |
Mice: Eight weeks of a Western diet (21% fat, 0.15% cholesterol; TD.88137) is given to eight-week-old female LDLRKO mice in order to conduct atherosclerosis studies. In order to measure the lesions in the innominate artery and the aortic root region, one group of mice (the baseline group) is put to death at this time. In the baseline group, an atherosclerotic lesion involving the entire aorta is not investigated. Prior to their demise, the surviving mice are split into two groups and given the subsequent diets for an additional 15 weeks: group 1, which is a chow diet with 5% fat (AIN-76A Rodent Diet); and group 2, which is a chow diet plus 1.25% (wt/wt) hydroxycholic acid. For other studies, 8-wk-old female LDLRKO mice are fed a chow diet or chow diet + 1.25% Hyodeoxycholic acid for 3 wk before phenotype measurements. Weekly records are kept on food intake and body weight. By using Bruker Minispec software with Eco Medical Systems software, magnetic resonance imaging (MRI) is used to measure the lean mass and total body fat mass of animals[2].
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
6alpha-Hydroxylithocholic acid is a known human metabolite of Lithocholic Acid. |
| References |
|
| Additional Infomation |
Hyodeoxycholic acid is a member of the class of 5beta-cholanic acids that is (5beta)-cholan-24-oic acid substituted by alpha-hydroxy groups at positions 3 and 6. It has a role as a human metabolite and a mouse metabolite. It is a bile acid, a member of 5beta-cholanic acids, a 6alpha,20xi-murideoxycholic acid and a C24-steroid. It is functionally related to a cholic acid. It is a conjugate acid of a hyodeoxycholate.
Hyodeoxycholic Acid has been used in trials studying the treatment of Hypercholesterolemia. |
| Molecular Formula |
C24H40O4
|
|---|---|
| Molecular Weight |
392.5720
|
| Exact Mass |
392.292
|
| CAS # |
83-49-8
|
| Related CAS # |
Murideoxycholic acid; 668-49-5; Hyodeoxycholic acid sodium; 10421-49-5; Hyodeoxycholic acid-d5
|
| PubChem CID |
5283820
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
547.1±25.0 °C at 760 mmHg
|
| Melting Point |
200-201 °C(lit.)
|
| Flash Point |
298.8±19.7 °C
|
| Vapour Pressure |
0.0±3.3 mmHg at 25°C
|
| Index of Refraction |
1.543
|
| LogP |
5
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
28
|
| Complexity |
605
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C[C@@H]([C@H]4[C@@]3(CC[C@H](C4)O)C)O)C
|
| InChi Key |
DGABKXLVXPYZII-SIBKNCMHSA-N
|
| InChi Code |
InChI=1S/C24H40O4/c1-14(4-7-22(27)28)17-5-6-18-16-13-21(26)20-12-15(25)8-10-24(20,3)19(16)9-11-23(17,18)2/h14-21,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15-,16+,17-,18+,19+,20+,21+,23-,24-/m1/s1
|
| Chemical Name |
(4R)-4-[(3R,5R,6S,8S,9S,10R,13R,14S,17R)-3,6-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
|
| Synonyms |
HDCA; Hyodeoxycholic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 78~100 mg/mL (198.7~254.7 mM)
Ethanol: ~78 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.37 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.37 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.37 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5473 mL | 12.7366 mL | 25.4732 mL | |
| 5 mM | 0.5095 mL | 2.5473 mL | 5.0946 mL | |
| 10 mM | 0.2547 mL | 1.2737 mL | 2.5473 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
